Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allurion Technologies, Inc.

< Previous 1 2 Next >
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces New Publications on Long-Term Weight Loss Results with the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Present at Jefferies Global Healthcare Conference
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Report First Quarter 2025 Financial Results on May 14, 2025
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Postponement of Special Meeting of Stockholders
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Participate in Upcoming Investor Conferences
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Relaunches in France
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Announces Positive Topline Results From AUDACITY Trial
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
Allurion Technologies, Inc. Announces Reverse Stock Split
From Allurion Technologies, Inc.
Via Business Wire
Tickers ALUR
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.